Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

2.67 -4.3

Buy Sell

Overview

Share price change

24h

Current

Min

2.66

Max

2.69

Key metrics
By Trading Economics
Income	3.5M -24M
Sales	572K 3.2M
EPS	-0.4
Profit margin	-773.239
Employees	141
EBITDA	4.4M -23M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+459.7% upside

Dividends
By Acuity
Next Earnings	9 lis 2026

Market Stats
By TradingEconomics
Market Cap	8.5M 190M
Previous open	6.97
Previous close	2.67

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 wrz 2026, 23:31 UTC

S&P Global Manufacturing PMI for South Korea set to release on October 1, 2026, amid cautious market expectations influenced by rising energy prices and geopolitical tensions.

26 wrz 2026, 23:31 UTC

S&P/Case-Shiller Home Price Index Set for Release with Anticipated 2.2% Growth Amid Mixed Market Sentiment and Economic Pressures

26 wrz 2026, 23:31 UTC

Brazil's Industrial Production MoM data release on October 2, 2026, expected to show growth trends amid recent fluctuations.

26 wrz 2026, 23:22 UTC

U.S. Q2 GDP Growth Rate Forecasted at +1.6% Amid Economic Concerns and Market Volatility Ahead of September 30 Release

26 wrz 2026, 23:22 UTC

Upcoming PCE Price Index release on September 30 raises inflation concerns amid rising commodity prices and geopolitical tensions.

26 wrz 2026, 23:22 UTC

U.S. Personal Spending Expected to Rise 0.8% in August Amid Caution Over Inflation and Consumer Confidence Decline

26 wrz 2026, 23:22 UTC

Upcoming U.S. Retail Inventories Ex Autos Report on September 30 Expected to Reflect Consumer Demand Amid Mixed Economic Signals.

26 wrz 2026, 23:22 UTC

U.S. Goods Trade Balance Report Set for Release Amid Anticipated $108.5 Billion Deficit and Positive Tariff Negotiations with China

26 wrz 2026, 23:22 UTC

US Personal Income Expected to Rise 0.4% in August Amid Economic Recovery and Inflation Concerns

26 wrz 2026, 23:22 UTC

U.S. Wholesale Inventories Expected to Rise 1.1% Amid Mixed Investor Sentiment and Inflation Concerns Ahead of September Release

26 wrz 2026, 23:22 UTC

U.S. GDP Price Index Expected to Rise 0.064% Amid Mixed Economic Sentiment and Inflation Concerns Ahead of September Release

26 wrz 2026, 23:22 UTC

Core PCE Price Index MoM for August 2026 set to release on September 30, with a forecasted increase of 0.3%, amid cautious investor sentiment and rising treasury yields impacting Fed policy outlook.

26 wrz 2026, 23:22 UTC

U.S. PCE Price Index Release on September 30 Expected to Show 0.4% Monthly Increase Amid Inflation Concerns and Market Volatility

26 wrz 2026, 23:11 UTC

Cautious Market Anticipates 70,000 Job Increase in Upcoming ADP Employment Report Amid Recent Underperformance

26 wrz 2026, 23:11 UTC

Mexican Business Confidence Remains Cautious Ahead of October EMOE Release Amid U.S. Economic Concerns

26 wrz 2026, 23:11 UTC

Correlated Moves

Avalanche is trading higher, continuing its upward trend since Friday, while Ethereum remains little changed amid broader market support from easing oil prices and Treasury yields.

26 wrz 2026, 23:01 UTC

Canada's Preliminary Monthly GDP Release on September 29 Expected to Show Stability Amid Economic Challenges and Trade Tensions.

26 wrz 2026, 23:01 UTC

South Korea's October 1 export report expected to show continued strong growth, following August's impressive 68.7% surge driven by memory chip demand.

26 wrz 2026, 22:51 UTC

Japan's unemployment rate forecasted to drop slightly to 2.4% in August, amid cautious market optimism and concerns over currency depreciation and rising interest rates ahead of the October release.

26 wrz 2026, 22:51 UTC

South Africa's Balance of Trade report on September 30, 2026, expected to show continued trade surplus amid cautious optimism in exports and declining imports.

26 wrz 2026, 22:51 UTC

Germany's Inflation Rate Release on September 30, 2026: Consumer Confidence Declines Amid Rising Energy Prices and Economic Uncertainty.

26 wrz 2026, 22:51 UTC

Japan's Tankan Index Set for Positive Release Amid Cautious Market Optimism and Global Economic Pressures

26 wrz 2026, 22:51 UTC

Germany's Inflation Rate Expected to Rise 0.5% Amid Declining Consumer Confidence Due to Soaring Energy Prices

26 wrz 2026, 22:51 UTC

Macro News

The Russell 2000 Index is trading lower in after-hours, reflecting a slight decline since Friday's close, amid rising delinquency rates in the commercial real estate sector.

26 wrz 2026, 22:51 UTC

Macro News

The Dow Jones Index is lower in after-market trading, amid trade tariff discussions and rising delinquency rates in commercial real estate.

26 wrz 2026, 22:51 UTC

Macro News

The FTSE 100 Index has advanced modestly in after-market hours, following a U.S.-China tariff agreement on $30 billion in goods.

26 wrz 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Hits 7.12%, Highest Since May, Amid Rising Treasury Yields and Inflation Concerns

26 wrz 2026, 22:40 UTC

Macro News

The DAX 30 Index is trading modestly lower in after-market hours, continuing its downward trend amid ongoing macroeconomic concerns and trade developments.

26 wrz 2026, 22:31 UTC

Japan's Industrial Production Expected to Rise 1.7% in August Amidst Cautious Optimism and Global Uncertainties

26 wrz 2026, 22:31 UTC

Japan's Retail Sales YoY data for August expected to rise 3.3% amid cautious optimism and inflation concerns, with market focus on currency valuation and global trends.

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

459.7% upside

12 Months Forecast

Average 15 USD 459.7%

High 25 USD

Low 8 USD

Based on 4 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.